Helen V. Hsieh

Helen V. Hsieh

Auto-generated profile, based on publicly available information

Helen V. Hsieh

Intellectual Ventures Laboratory, 14360 SE Eastgate Way, Bellevue, Washington 98007, United States

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 June 2019 in Lab on a Chip
Verified
Journal Article
Open access
PDF file
JBJoshua D. Bishop
Joshua D. Bishop
HHHelen V. Hsieh
Helen V. Hsieh
DGDavid J. Gasperino
David J. Gasperino
BWBernhard H. Weigl
Bernhard H. Weigl
This critical review organizes and evaluates state-of-the-art approaches to LFA sensitivity enhancement from a system-level perspective.

21 September 2021 in ACS Omega
Verified
Journal Article
Open access
DCDavid M. Cate
David M. Cate
JBJoshua D. Bishop
Joshua D. Bishop
HHHelen V. Hsieh
Helen V. Hsieh
VGVeronika A. Glukhova
Veronika A. Glukhova
LALuis F. Alonzo
Luis F. Alonzo
KNKevin P. Nichols
Kevin P. Nichols
The global COVID-19 pandemic has created an urgent demand for large numbers of inexpensive, accurate, rapid, point-of-care diagnostic tests. Analyte-based assays are suitably rapid and inexpensive and can be rapidly mass-produced, but for sufficiently accurate performance, they require highly optimized antibodies and assay conditions. We used an automated liquid handling system, customized to handle arrays of lateral flow (immuno)assays (LFAs) in a high-throughput screen, to identify anti-nucleocapsid antibodies that will perform optimally in an LFA. We tested 1021 anti-nucleocapsid antibody pairs as LFA capture and detection reagents with the goal of highlighting pairs that have the greatest affinity for the nucleocapsid protein of SARS-CoV-2 within the LFA format. In contrast to traditional antibody screening methods (e.g., ELISA, bio-layer interferometry), the method described here integrates real-time reaction kinetics with transport in, and immobilization directly onto, nitrocellulose. We have identified several candidate antibody pairs that are suitable for further development of an LFA for SARS-CoV-2.